348
Participants
Start Date
September 1, 2010
Primary Completion Date
August 1, 2011
Study Completion Date
August 26, 2011
Vilanterol
Vilanterol inhalation powder inhaled orally once daily for 12 weeks
Salmeterol Inhalation Powder
Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
Placebo Inhalation Powder NDPI
Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
Placebo Inhalation Powder Diskus
Placebo inhalation powder inhaled orally twice daily for 12 weeks
GSK Investigational Site, Großhansdorf
GSK Investigational Site, Raleigh
GSK Investigational Site, Orangeburg
GSK Investigational Site, Clinton
GSK Investigational Site, Chester
GSK Investigational Site, Lawrenceville
GSK Investigational Site, Tallahassee
GSK Investigational Site, Orlando
GSK Investigational Site, Cincinnati
GSK Investigational Site, Dnipropetrovsk
GSK Investigational Site, Dnipropetrovsk
GSK Investigational Site, Mainz
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Kharkiv
GSK Investigational Site, Kharkiv
GSK Investigational Site, Oklahoma City
GSK Investigational Site, Ivano-Frankivsk
GSK Investigational Site, Gauting
GSK Investigational Site, Donetsk
GSK Investigational Site, Huntington Beach
GSK Investigational Site, Simferopol
GSK Investigational Site, Yalta
GSK Investigational Site, Skillman
GSK Investigational Site, Lima
GSK Investigational Site, San Isidro
GSK Investigational Site, Lima
GSK Investigational Site, San Miguel
GSK Investigational Site, Callao
GSK Investigational Site, Chrzanów
GSK Investigational Site, Krakow
GSK Investigational Site, Krakow
GSK Investigational Site, Krakow
GSK Investigational Site, Lublin
GSK Investigational Site, Kyiv
Lead Sponsor
GlaxoSmithKline
INDUSTRY